Healthcare Sales & Marketing Network News: anxiety disorder

Searching News Database: anxiety disorder

HSMN NewsFeed - 4 Nov 2016
The GeneSight(R) Precision Medicine Test Drives Significant Medication Cost Savings in Patients with Generalized Anxiety Disorder
Diagnostics Personalized Medicine

HSMN NewsFeed - 21 Oct 2015
Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Feb 2013
Top-Line Data Show Lyrica Met Primary Endpoint in Clinical Trial as Adjunctive Therapy versus Levetiracetam in Patients with Partial Onset Seizures
Biopharmaceuticals Neurology

HSMN NewsFeed - 22 Nov 2010
Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta(R) Delayed-Release 20, 30 and 60 mg Capsules
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 19 May 2010
STELARA(TM) Significantly Improves Symptoms of Depression, Anxiety and Health-Related Quality of Life in Patients With Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 3 Feb 2010
Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New Study
Biopharmaceuticals

HSMN NewsFeed - 30 Nov 2009
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Sep 2009
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
Biopharmaceuticals

HSMN NewsFeed - 2 Jun 2009
Clinical Data, Inc. Announces Positive Results from Second Phase III Trial of Vilazodone for Depression
Biopharmaceuticals

HSMN NewsFeed - 29 Apr 2009
Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post-Traumatic Peripheral Nerve Pain, New Data Show
Biopharmaceuticals Neurology

HSMN NewsFeed - 22 Apr 2009
MediciNova Reports Final Data from Phase II MN-221 Emergency Department Clinical Trial (MN-221-CL-006); Hospitalization Rates Decrease 45 Percent With MN-221 Plus Standardized Care in Asthma Patients
Biopharmaceuticals

HSMN NewsFeed - 24 Feb 2009
Pfizer Discontinues Development of Two Phase 3 Compounds
Biopharmaceuticals

HSMN NewsFeed - 30 Jan 2009
Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
Biopharmaceuticals

HSMN NewsFeed - 23 Dec 2008
MediciNova Proposes to Acquire Avigen, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 10 Dec 2008
Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
Biopharmaceuticals

HSMN NewsFeed - 28 Nov 2008
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Biopharmaceuticals

HSMN NewsFeed - 18 Nov 2008
Impax Sued Based on Anda for Generic Cymbalta(R)
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 17 Nov 2008
Mylan Receives Tentative FDA Approval for the Generic Version of the Antidepressant Effexor XR(R)
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 8 Oct 2008
FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression
Devices Neurology FDA

HSMN NewsFeed - 26 Sep 2008
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
Biopharmaceuticals Licensing

HSMN NewsFeed - 8 Sep 2008
MediciNova to Present At Merriman Curhan Ford's 5th Annual Investor Summit 2008
Biopharmaceuticals

HSMN NewsFeed - 25 Aug 2008
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
Biopharmaceuticals

HSMN NewsFeed - 22 Aug 2008
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
Biopharmaceuticals Regulatory

HSMN NewsFeed - 31 Jul 2008
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 30 Jul 2008
Noven Announces Final FDA Approval of Stavzor(TM) for the Treatment of Bipolar Disorder, Seizures and Migraine Headaches
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Jun 2008
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 Jun 2008
FDA Approves Cymbalta(R) for the Management of Fibromyalgia
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Jun 2008
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
Biopharmaceuticals

HSMN NewsFeed - 10 Jun 2008
Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
Biopharmaceuticals

HSMN NewsFeed - 29 May 2008
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Biopharmaceuticals

HSMN NewsFeed - 23 May 2008
Osmotica Pharmaceutical Receives FDA Approval to Market Novel Forms of Extended Release Venlafaxine HCl
Biopharmaceuticals FDA

HSMN NewsFeed - 20 May 2008
Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Biopharmaceuticals Neurology

HSMN NewsFeed - 12 May 2008
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
Biopharmaceuticals

HSMN NewsFeed - 12 May 2008
LUNESTA(R) Study of Patients with Insomnia and Co-Morbid Generalized Anxiety Disorder (GAD) Published in Archives of General Psychiatry
Biopharmaceuticals

HSMN NewsFeed - 8 May 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
Biopharmaceuticals

HSMN NewsFeed - 14 Apr 2008
Jazz Pharmaceuticals' LUVOX CR Is Now Available for Patients With Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Biopharmaceuticals

HSMN NewsFeed - 19 Mar 2008
Forest Laboratories Announces Resignation of Ivan Gergel, MD
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Mar 2008
BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
Biopharmaceuticals Neurology Venture Capital Personnel

HSMN NewsFeed - 28 Feb 2008
FDA Approves LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Biopharmaceuticals

HSMN NewsFeed - 1 Feb 2008
MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
Biopharmaceuticals Neurology

HSMN NewsFeed - 22 Jan 2008
Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor
Biopharmaceuticals Licensing

HSMN NewsFeed - 18 Jan 2008
In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
Biopharmaceuticals

HSMN NewsFeed - 4 Jan 2008
Ambien CR(R) (zolpidem tartrate extended-release) tablets CIV Improved Chronic Insomnia in Patients with Co-Morbid Generalized Anxiety Disorder
Biopharmaceuticals

HSMN NewsFeed - 31 Dec 2007
Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Dec 2007
FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 5 Dec 2007
New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression
Biopharmaceuticals

HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Nov 2007
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Nov 2007
Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
Biopharmaceuticals

HSMN NewsFeed - 18 Oct 2007
IMPAX Announces Tentative Approval of Generic Effexor XR(R)
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 16 Oct 2007
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 5 Sep 2007
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 4 Sep 2007
Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Biopharmaceuticals

HSMN NewsFeed - 21 Aug 2007
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
Biopharmaceuticals

HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Biopharmaceuticals

HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Biopharmaceuticals

HSMN NewsFeed - 27 Jul 2007
Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Jul 2007
Cortex to Resume Clinical Trial with AMPAKINE(R) CX717 in Alzheimer-PET Scan Study after FDA Approves Protocol with Higher Doses of Drug
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 26 Jun 2007
MediciNova Announces New Strategic Initiative
Biopharmaceuticals

HSMN NewsFeed - 31 May 2007
Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
Biopharmaceuticals Neurology

HSMN NewsFeed - 29 May 2007
IMPAX Receives Final FDA Approval for Generic Xanax(R) XR Extended Release Tablets
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 23 May 2007
Study Suggests Strattera(R) Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse
Biopharmaceuticals

HSMN NewsFeed - 21 May 2007
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
Biopharmaceuticals

HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology

HSMN NewsFeed - 21 May 2007
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
Biopharmaceuticals Cardiology

HSMN NewsFeed - 17 May 2007
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 10 May 2007
Cortex and the University of Alberta Complete Patent License Agreement
Biopharmaceuticals Neurology Licensing

HSMN NewsFeed - 3 May 2007
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Biopharmaceuticals

HSMN NewsFeed - 1 May 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 27 Mar 2007
MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
Biopharmaceuticals Neurology

HSMN NewsFeed - 26 Feb 2007
FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Feb 2007
Jazz Pharmaceuticals, Inc. and Solvay Pharmaceuticals, Inc. Announce License Agreement for LUVOX(R) (Fluvoxamine Maleate) Tablets and Fluvoxamine Maleate Extended-Release Capsules in the United States
Biopharmaceuticals Licensing

HSMN NewsFeed - 18 Jan 2007
Cipralex Approved in Europe for the Treatment of Obsessive Compulsive Disorder
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Jan 2007
Forest Laboratories Announces Completion of Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 14 Dec 2006
Forest Laboratories Announces Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 5 Dec 2006
Data Show Sepracor's Lunesta(R) Improved Insomnia in Patients with Co-Existing Generalized Anxiety Disorder
Biopharmaceuticals

HSMN NewsFeed - 10 Nov 2006
MediciNova Appoints Shintaro Asako as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Nov 2006
MediciNova Announces the Acquisition of Two Novel Antithrombotic Agents from Meiji Seika Kaisha, Ltd.
Biopharmaceuticals Cardiology Acquisitions

HSMN NewsFeed - 28 Oct 2006
Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2
Biopharmaceuticals Neurology

HSMN NewsFeed - 23 Oct 2006
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Sep 2006
EPIX Pharmaceuticals Announces Top-line Results from Phase 3 Trial of PRX-00023 in Generalized Anxiety Disorder
Biopharmaceuticals

HSMN NewsFeed - 20 Sep 2006
EPIX Announces Australian Approval of Vasovist(TM)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 18 Sep 2006
Pfizer's Lyrica(R) Approved in Europe for Difficult-to-Treat Nerve Pain
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Sep 2006
Forest Laboratories Inc. Announces Appointment of Dr. Lawrence S. Olanoff as President and Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Jul 2006
Forest Announces Federal Court Upholds Lexapro(R) Patent
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 13 Jul 2006
EPIX Pharmaceuticals Retains Full Rights to Fibrin-Binding Imaging Agent EP-2104R as Schering AG Decides Not to Exercise Option for Development Program
Biopharmaceuticals Radiology

HSMN NewsFeed - 30 Jun 2006
EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist(TM) Approvable Letters
Biopharmaceuticals Radiology FDA

HSMN NewsFeed - 26 Jun 2006
Cephalon Announces Results from GABITRIL(R) Clinical Program in Generalized Anxiety Disorder
Biopharmaceuticals

HSMN NewsFeed - 24 May 2006
Indevus Announces Promising Phase II Data for Pagoclone In Stuttering
Biopharmaceuticals

HSMN NewsFeed - 24 May 2006
Predix Pharmaceuticals Achieves Full Enrollment for Phase III Clinical Trial of PRX-00023 in Generalized Anxiety Disorder
Biopharmaceuticals

HSMN NewsFeed - 23 May 2006
New Study Reports Venlafaxine Extended Release May Help Adult Patients Prevent New Episodes of Depression for Up to Two Years
Biopharmaceuticals

HSMN NewsFeed - 19 May 2006
Cyberonics Provides Update on Annual American Psychiatric Association Meeting Activities and Recent VNS Therapy Publications
Devices Neurology

HSMN NewsFeed - 17 May 2006
Cyberonics Announces Patient Enrollment in New TRD Dosing Study
Devices Neurology

HSMN NewsFeed - 9 May 2006
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder
Biopharmaceuticals FDA

Return to NewsFeed

Additional items found! 169

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 169 additional stories matching:
anxiety disorder
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.